BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise
I'm PortAI, I can summarize articles.
Oppenheimer initiates coverage on Aardvark Therapeutics with an "outperform" rating and a $35 price target, indicating potential stock growth. Aardvark's focus on Prader-Willi syndrome and obesity, with upcoming data on ARD-101 and ARD-201 drugs, is seen as a catalyst for stock movement. ARD-201 could offer alternatives to injectable therapies, aiding in weight management. Aardvark's stock has declined 9% since its Nasdaq debut.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments